Simeprevir: Clinical Trials

24 trials of Simeprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 1 withdrawn. 24 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 224Completed 23, Withdrawn 1

Follow Simeprevir: new trials by email Literature Review of Simeprevir trials Research Report on Simeprevir

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
AL-335, Odalasvir (ODV), Simeprevir (SMV) - Hepatitis C, Chronic
Phase 2CompletedJanssen Pharmaceutical K.K.332016-12-212019-09-11
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
AL-335, Odalasvir, Simeprevir - Hepatitis C, Chronic
Phase 2CompletedJanssen Research & Development, LLC3652016-11-092019-11-20
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
AL-335, Odalasvir (ODV), Simeprevir (SMV) - Chronic Hepatitis C
Phase 2CompletedAlios Biopharma Inc.1612015-10-312019-07-16
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Simeprevir (SMV), Ledipasvir (LDV), Sofosbuvir (SOF) - Hepatitis C, Chronic
Phase 2CompletedJanssen Sciences Ireland UC412015-05-192019-03-28
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk - Chronic Hepatitis C Infection
Phase 2CompletedHumanity and Health Research Centre1382015-05-152025-03-26
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Simeprevir (SMV) 150 mg, Daclatasvir (DCV) 60 mg - Renal Impairment, End-stage Renal Disease
Phase 2WithdrawnJanssen R&D Ireland2015-05-012015-07-17
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients
Sofosbuvir + Simeprevir + Ribavirin - Chronic Hepatitis C Virus Infection
Phase 2CompletedBeni-Suef University2032015-04-012020-05-12
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
Simeprevir, Daclatasvir - Hepatitis C, Chronic
Phase 2CompletedJanssen-Cilag International NV1062015-01-012017-03-16
Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects
LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV - Chronic Hepatitis C Infection
Phase 2CompletedHumanity and Health Research Centre182015-01-012016-03-01
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg - Hepatitis C Virus
Phase 2CompletedJanssen Research & Development, LLC682015-01-012017-03-01
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
Simeprevir, Sofosbuvir - Hepatitis C
Phase 2CompletedJanssen-Cilag International NV632014-12-012016-10-14
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection
Simeprevir, Sofosbuvir - Chronic Hepatitis C
Phase 2CompletedPeter J. Ruane, M.D.302014-10-012016-02-24
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
Simeprevir, Daclatasvir, Sofosbuvir - Hepatitis C, Chronic
Phase 2CompletedJanssen Research & Development, LLC402014-09-302025-02-04
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
Simeprevir, Sofosbuvir, Ribavirin - Hepatitits C
Phase 2CompletedJanssen Scientific Affairs, LLC462014-08-012016-11-11
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
Simeprevir, Daclatasvir, Ribavirin - Hepatitis C, Chronic
Phase 2CompletedJanssen R&D Ireland352013-12-122018-11-21
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
Samatasvir, Simeprevir, Ribavirin (RBV) - Chronic Hepatitis C Virus
Phase 2CompletedMerck Sharp & Dohme LLC1432013-03-012015-04-23
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
TMC647055, TMC435, Ritonavir - Chronic Hepatitis C
Phase 2CompletedJanssen R&D Ireland902012-10-012016-01-11
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
Daclatasvir, Simeprevir, Ribavirin - Hepatitis C Virus
Phase 2CompletedBristol-Myers Squibb2302012-07-012017-02-23
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
TMC435, PSI-7977 (GS7977), Ribavirin - Hepatitis C
Phase 2CompletedJanssen R&D Ireland1682012-01-012015-02-09
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
TMC435, Placebo, Peg-IFN-alfa-2a (P) - Hepatitis C
Phase 2CompletedTibotec Pharmaceuticals, Ireland4632009-10-012014-06-09

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Hepatitis C, Chronic (12)  ·  Hepatitis C (9)  ·  Fibrosis (1)  ·  Kidney Failure, Chronic (1)  ·  Liver Cirrhosis (1)  ·  Renal Insufficiency (1)

Sponsors

Janssen R&D Ireland (4)  ·  Tibotec Pharmaceuticals, Ireland (4)  ·  Janssen Research & Development, LLC (3)  ·  Humanity and Health Research Centre (2)  ·  Janssen Pharmaceutical K.K. (2)  ·  Janssen-Cilag International NV (2)  ·  Alios Biopharma Inc. (1)  ·  Beni-Suef University (1)  ·  Bristol-Myers Squibb (1)  ·  Janssen Sciences Ireland UC (1)  ·  Janssen Scientific Affairs, LLC (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Peter J. Ruane, M.D. (1)

Countries

Germany (9)  ·  Belgium (8)  ·  United States (8)  ·  France (6)  ·  Spain (6)  ·  Poland (5)  ·  Canada (4)  ·  United Kingdom (4)  ·  New Zealand (3)  ·  Australia (2)  ·  Austria (2)  ·  China (2)  ·  Hungary (2)  ·  Japan (2)  ·  Norway (2)

Top investigators

George Lau (1)  ·  George Lau, MD (1)  ·  Peter J Ruane, MD (1)

Results publications

PMID 25164700, PMID 25445400, PMID 22024518, PMID 22885330, PMID 23907700, PMID 24005956, PMID 24184810, PMID 25078309, PMID 26453968, PMID 27790789, PMID 27878906, PMID 27896858, PMID 27917405, PMID 28135777, PMID 28295849, PMID 28569206, PMID 28971875, PMID 29274193, PMID 30598598, PMID 32270053, PMID 38587329

NIH funding

2014 (2), 2015 (2), 2008 (1), 2009 (1)